Pharma News

The Serum Institute of India (SII) has joined hands with the University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of an experimental vaccine targeting the Bundibugyo strain of Ebola virus, a deadly pathogen currently driving outbreaks in the Democratic Republic of Congo (DRC) and Uganda. CEPI has committed up to 8.6 million USD to support the vaccine's advancement toward clinical testing.

Prescribing antibiotics for common sore throats may have only a minimal impact on preventing serious streptococcal infections, according to new research from the University of Gothenburg. The findings challenge a widely debated rationale for antibiotic use and highlight the importance of recognizing early signs of severe illness instead.

The U.S. Food and Drug Administration (FDA) has approved Xocova (ensitrelvir), developed by Japanese pharmaceutical company Shionogi & Co., for the prevention of COVID-19 following exposure to an infected individual. The approval makes Xocova the first and only oral antiviral therapy authorized in the United States for post-exposure prophylaxis of COVID-19.

A new review suggests that routinely prescribing antibiotics after hospital discharge may provide little benefit for children recovering from complicated acute appendicitis (CAA). The findings add to growing concerns about unnecessary antibiotic exposure and its potential role in adverse effects and antimicrobial resistance.

Researchers from The University of Osaka have developed an innovative mRNA-based treatment that could help protect the heart from long-term damage following a heart attack. In a new study, scientists found that delivering a combination of five therapeutic mRNAs directly to damaged heart tissue significantly improved heart function and survival in mice that had experienced myocardial infarction (heart attack).

A commonly prescribed medicine used for neuropathic pain, epilepsy, and anxiety disorders is increasingly coming under scrutiny due to its growing misuse and dependence potential. A recent study published in the Indian Journal of Medical Research (IJMR) has highlighted the rising pattern of pregabalin misuse in India and emphasized the urgent need for regulatory and public health interventions.

OrigAMI-4 study shows strong tumor responses in patients with recurrent or metastatic head and neck cancer after standard treatments fail. Johnson & Johnson has announced promising clinical results for its investigational therapy RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in patients with advanced head and neck squamous cell carcinoma (HNSCC), a disease where treatment options remain limited once standard therapies stop working.

Atherosclerosis, the gradual buildup of fatty deposits inside arteries, remains one of the leading causes of heart attacks and strokes worldwide. While inflammation has long been recognized as a major contributor to the disease, new research from scientists at Ludwig Maximilian University of Munich suggests that certain inflammatory immune cells may also play a protective role in slowing its progression.